Summit Therapeutics Files Marketing Application for Lung Cancer Therapy

MT Newswires Live01-12

Summit Therapeutics (SMMT) announced on Monday that it has submitted a marketing application to the US Food and Drug Administration, seeking approval for its experimental drug, ivonescimab, in combination with chemotherapy for the second-line or later treatment of certain patients with a type of non-small cell lung cancer.

The company said the submission is based on results from a phase III trial.

If the application is accepted under standard review timelines, Summit said it expects an FDA decision in Q4.

As of December 31, 2025, Summit stated that its preliminary unaudited cash, cash equivalents, and short-term investments totaled approximately $710 million, pending completion of financial closing procedures.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment